ANGLE PLC S/ADR - ANPCY STOCK NEWS

Welcome to our dedicated page for ANGLE PLC S/ADR news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on ANGLE PLC S/ADR stock.

ANGLE PLC S/ADR (ANPCY) is a world-leading liquid biopsy company specializing in innovative circulating tumour cell (CTC) solutions for research, drug development, and clinical oncology. The company's proprietary Parsortix system efficiently harvests CTCs from blood samples, enabling downstream molecular analysis for comprehensive biomarker assessment. ANGLE's cutting-edge technologies, such as the Portrait+ CTC Staining Kit, enable the identification and analysis of diverse CTC phenotypes and clusters, providing valuable insights into cancer progression, metastasis, and treatment response. With a focus on diagnostic products and clinical services, ANGLE continues to drive advancements in precision medicine through its state-of-the-art liquid biopsy solutions.

11/09/2023 02:00 AM

News

Angle PLC Announces Launch of PD-L1 Test to Support Cancer Studies

Rhea-AI Summary

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) announces the launch of its Portrait PD-L1 test, a minimally invasive liquid biopsy using CTCs from the Parsortix system to determine PD-L1 status in cancer patients. The test aims to provide accurate, repeatable, and precise results for CTC PD-L1 biomarker expression, allowing real-time assessment of the biomarker status, which may address the fundamental flaw in current PD-L1 tests via a simple blood test. The global PD-1 and PD-L1 immunotherapy market is currently valued at US $36.9 billion per annum, and analysts predict the market to reach US $109.1 billion by 2032.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

10/25/2023 02:00 AM

News

Angle PLC Announces Supporting characterisation of CTCs in HNSCC

Rhea-AI Summary

ANGLE plc announces the publication of a study using the Parsortix system that sheds new light on the characteristics of circulating tumor cells (CTCs) in Head and Neck Squamous Cell Carcinoma (HNSCC). The study demonstrates the feasibility of using mass cytometry for the comprehensive characterization of CTCs captured by the Parsortix system, providing a deep understanding of their phenotypic status and diversity. The findings offer the potential for the development of more precise and personalized treatment strategies for HNSCC patients.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

10/03/2023 02:00 AM

News

Angle PLC Announces Parsortix Outperforms Standard for DTC Harvest

Rhea-AI Summary

PARSORTIX SYSTEM OUTPERFORMS CURRENT LABORATORY STANDARD FOR DISSEMINATED TUMOUR CELL HARVEST

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.72%

Tags

09/29/2023 02:00 AM

News

Angle PLC Announces Parsortix System Showcased at ACTC Conference

Rhea-AI Summary

ANGLE plc showcased the Parsortix system at the Advances in Circulating Tumor Cells conference, receiving positive feedback. Key highlights include predictive CTC biomarkers for treatment resistance in NSCLC, clinical significance of mesenchymal CTCs, and dual analysis of CTCs and ctDNA. ANGLE plans to expand translational research use and grow biopharma services business.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

09/07/2023 02:00 AM

News

Angle PLC Announces Interim Results for the Period Ended 30 June 2023

Rhea-AI Summary

ANGLE plc announces interim results for the period ended 30 June 2023

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.23%

Tags

09/04/2023 02:00 AM

News

Angle PLC Announces ANGLE launch of Portrait Flex assay

Rhea-AI Summary

ANGLE plc announces launch of Portrait Flex assay

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

08/15/2023 02:00 AM

News

Angle Notice of Interim Results

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/28/2023 12:45 PM

News

Angle PLC Announces Result of 2023 Annual General Meeting

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-22.56%

Tags

06/27/2023 08:00 AM

News

Angle PLC Announces Standard Form for Notification of Major Holdings

Rhea-AI Summary

ANGLE plc Announces Standard Form for Notification of Major Holdings

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/05/2023 02:00 AM

News

ANGLE Announces Senior Management Appointments

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

FAQ

What is the current stock price of ANGLE PLC S/ADR (ANPCY)?

The current stock price of ANGLE PLC S/ADR (ANPCY) is $1.35 as of December 18, 2024.

What is the market cap of ANGLE PLC S/ADR (ANPCY)?

The market cap of ANGLE PLC S/ADR (ANPCY) is approximately 47.4M.

What is ANGLE PLC S/ADR known for?

ANGLE is a world-leading liquid biopsy company specializing in innovative circulating tumour cell (CTC) solutions for research, drug development, and clinical oncology.

What technologies does ANGLE use for CTC analysis?

ANGLE utilizes the Parsortix system for efficient harvesting of CTCs from blood samples, enabling downstream molecular analysis for comprehensive biomarker assessment.

How does ANGLE's Portrait+ CTC Staining Kit benefit cancer research?

The Portrait+ CTC Staining Kit enables the identification and analysis of diverse CTC phenotypes and clusters, providing valuable insights into cancer progression, metastasis, and treatment response.

What is the focus of ANGLE's commercial businesses?

ANGLE's commercial focus is on diagnostic products and clinical services, offering advanced liquid biopsy solutions and custom assay development for pharma.